SCHEMBL24309919

SCHEMBL24309919

CNC(=O)c1cccc(Oc2nc(NS(=O)(=O)c3cnn(C)c3)nc(-c3ccccc3C)c2C)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 6/20 0.40
▸ EGFR P00533 3/20 0.40
▸ KDR P35968 3/20 0.40
▸ F10 P00742 2/20 0.40
▸ ULK1 O75385 3/20 0.37
▸ POLB P06746 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ FGFR3 P22607 3/20 0.37
▸ CCR2 P41597 3/20 0.36
▸ NTRK1 P04629 1/20 0.36
▸ PDGFRB P09619 1/20 0.36
▸ KIT P10721 1/20 0.36
▸ FLT3 P36888 1/20 0.36
▸ F2 P00734 1/20 0.35
▸ PTK2 Q05397 1/20 0.35
▸ HTR1A P08908 1/20 0.35
▸ HTR7 P34969 1/20 0.35
▸ AXL P30530 1/20 0.34
▸ TYRO3 Q06418 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29566810 1.00 FGFR1 (0.40) FGFR1EGFRKDRF10ULK1
SCHEMBL26811489 0.92 FGFR1 (0.38) FGFR1EGFRKDRF10ULK1
SCHEMBL29567325 0.91 FGFR1 (0.39) FGFR1EGFRKDRHPGDSMN1; SMN2
SCHEMBL24309822 0.91 FGFR1 (0.39) FGFR1EGFRKDRHPGDSMN1; SMN2
SCHEMBL29567228 0.87 HTR1A (0.40) FGFR1EGFRKDRHPGDSMN1; SMN2
SCHEMBL24309861 0.87 HTR1A (0.40) FGFR1EGFRKDRHPGDSMN1; SMN2
SCHEMBL29566629 0.86 GPR119 (0.40) HTR1AHTR7
SCHEMBL26808782 0.86 GPR119 (0.40) HTR1AHTR7
SCHEMBL24309774 0.86 HTR1A (0.34) FGFR1EGFRKDRFGFR3PTK2
SCHEMBL29566573 0.86 HTR1A (0.34) FGFR1EGFRKDRFGFR3PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B FGFR1 2391/4885EGFR 818/4885KDR 4439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback